News Sentiment

SRPT sentiment intelligence

Sarepta Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 69 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 18.95 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 60

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-1.7% over one week, +23.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced

Market Reaction

Balanced read

62/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction -1.7% Price digesting
Trend fit Trend inactive 23.8% over four weeks
Fair value -75.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 44
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 60
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
TradingView 8
simplywall.st 6
Stocktwits 4
Sarepta Therapeutics 4
Simply Wall Street 3
DirectorsTalk Interviews 3
Stock Titan 3

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 23
Analyst action 8
Regulatory and legal 4
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 69
Stocktwits Direct company coverage

SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced

Sarepta Therapeutics (SRPT) shares jumped 35% after releasing early clinical data for its rare muscle disorder programs, DM1 and FSHD1. While some analysts found the data promising, others expressed caution due to limitations in the data and safety concerns. The company's investi

Tone
Positive 63/100
Event
Market update
Published
16 Jul 2026 12:10
Source
Stocktwits
Stock Traders Daily Direct company coverage

Trading Systems Reacting to (SRPT) Volatility

This article from Stock Traders Daily discusses the volatility of Sarepta Therapeutics Inc. (NASDAQ: SRPT), highlighting conflicting sentiment across different time horizons. It provides AI-generated trading strategies including position trading, momentum breakout, and risk hedgi

Tone
Negative 37/100
Event
Market update
Published
16 Jul 2026 01:40
Source
Stock Traders Daily
Simply Wall Street Direct company coverage

Is Sarepta Therapeutics (SRPT) Undervalued Following FDA Progress On AMONDYS 45 And VYONDYS 53?

Sarepta Therapeutics (SRPT) is being re-evaluated after the FDA accepted supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53, Duchenne muscular dystrophy therapies. While the stock has seen a recent 30-day rebound, its long-term shareholder returns remain negative. T

Tone
Positive 67/100
Event
Market update
Published
15 Jul 2026 12:10
Source
Simply Wall Street
Supply Chain Digital Direct company coverage

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Sarepta Therapeutics, Inc. (SRPT)

Johnson Fistel, PLLP is investigating potential claims on behalf of long-term shareholders of Sarepta Therapeutics, Inc. (SRPT) who held shares continuously since before June 22, 2023. The investigation concerns alleged breaches of fiduciary duty by Sarepta's officers and directo

Tone
Negative 30/100
Event
Regulatory and legal
Published
14 Jul 2026 08:11
Source
Supply Chain Digital
Quartr Direct company coverage

Sarepta Therapeutics (SRPT) Proxy filing Summary

Sarepta Therapeutics (SRPT) has released a summary of its proxy filing for the upcoming Annual Meeting scheduled for June 4, 2026. The filing outlines key proposals including the election of five Class I directors, executive compensation, equity and stock purchase plans, and audi

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 23:40
Source
Quartr
Stocktwits Direct company coverage

This Analyst Sees 34% Upside For SRPT Stock — Here's Why They Expect A Sustained Rally Next

Wolfe Research upgraded Sarepta Therapeutics (SRPT) to 'Outperform' with a $27 price target, citing potential catalysts like new data in H2 2026 and readthrough from Novartis's neuromuscular disease programs. The firm believes SRPT, despite recent transient gains, is poised for a

Tone
Positive 67/100
Event
Analyst action
Published
09 Jul 2026 10:47
Source
Stocktwits
Investing.com Direct company coverage

Wolfe Research upgrades Sarepta Therapeutics stock rating on pipeline outlook

Wolfe Research upgraded Sarepta Therapeutics (NASDAQ:SRPT) to Outperform from Peerperform, setting a price target of $27.00, implying a 33% upside. The upgrade is attributed to anticipated data releases, increased investor focus on the company

Tone
Positive 89/100
Event
Analyst action
Published
08 Jul 2026 21:41
Source
Investing.com
Quartr Direct company coverage

Sarepta Therapeutics (SRPT) Q4 2025 earnings summary

Sarepta Therapeutics reported strong financial results for Q4 and full-year 2025, with $2.2 billion in total revenues and a positive operating cash flow. The company launched ELEVIDYS in Japan, which triggered a $40 million milestone, and saw durable benefits from its three-year

Tone
Positive 67/100
Event
Earnings
Published
08 Jul 2026 10:09
Source
Quartr
TradingView Direct company coverage

Price to book forward of Sarepta Therapeutics, Inc. – NASDAQ:SRPT

This article provides financial data for Sarepta Therapeutics, Inc. (NASDAQ: SRPT), specifically focusing on its "Price to book forward" metric. It appears to be a stub or a data point from a larger financial platform like TradingView, indicating the value and change of this fina

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 01:40
Source
TradingView
TradingView Direct company coverage

Price to book forward of Sarepta Therapeutics, Inc. – LSE:0L35

This article displays financial information for Sarepta Therapeutics, Inc., specifically its "Price to book forward." It shows the company's ticker symbol (0L35) on the London Stock Exchange and outlines the various sections available on the TradingView platform for this security

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 23:11
Source
TradingView
Simply Wall Street Direct company coverage

Why Sarepta Therapeutics (SRPT) Is Up 12.7% After FDA Accepts sNDAs Backed By ESSENCE Data

Sarepta Therapeutics' stock rose 12.7% after the FDA accepted supplemental New Drug Applications (sNDAs) for its Duchenne muscular dystrophy (DMD) therapies, AMONDYS 45 and VYONDYS 53, for conversion to traditional approvals. These applications are backed by Phase 3 ESSENCE data

Tone
Positive 67/100
Event
Market update
Published
07 Jul 2026 16:11
Source
Simply Wall Street
TradingView Direct company coverage

Enterprise value to EBITDA forward of Sarepta Therapeutics, Inc. – LSE:0L35

This article provides financial data for Sarepta Therapeutics, Inc. (LSE:0L35), specifically focusing on its enterprise value to EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) forward metric. It appears to be a stub or data-point article from TradingView

Tone
Neutral 50/100
Event
Earnings
Published
07 Jul 2026 02:09
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Sarepta Therapeutics, Inc. – LSE:0L35

This article provides financial information for Sarepta Therapeutics, Inc. (LSE:0L35), specifically focusing on its forward price-to-earnings ratio. The content primarily lists market data sources and disclaimers from TradingView and its partners. It does not provide specific val

Tone
Neutral 50/100
Event
Earnings
Published
06 Jul 2026 11:42
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Sarepta Therapeutics, Inc. – LSE:0L35

This article provides financial data for Sarepta Therapeutics, Inc. (LSE:0L35) with a specific focus on its enterprise value to EBIT forward. It is presented in a data-centric format common on financial platforms like TradingView, indicating the period, value, and change metrics

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 22:40
Source
TradingView
Finviz Direct company coverage

SRPT - Sarepta Therapeutics Inc Volatility & Greeks

This article provides a detailed financial overview of Sarepta Therapeutics Inc (SRPT), including its stock performance, key financial metrics, and market volatility data. It lists various ratios, growth rates, insider and institutional ownership, and analyst recommendations. The

Tone
Neutral 50/100
Event
Analyst action
Published
04 Jul 2026 11:09
Source
Finviz
TradingView Direct company coverage

ETFs Investing in Sarepta Therapeutics, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Sarepta Therapeutics, Inc. It provides detailed information for each ETF, including market value, weight of Sarepta Therapeutics stock, issuer, management style, focus, expense ratio, assets under managem

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 09:41
Source
TradingView
Stock Titan Direct company coverage

If You Invested $1,000 in Sarepta Therapeutics Inc (SRPT)

This article analyzes the historical performance of an investment in Sarepta Therapeutics Inc (SRPT), detailing returns over 1, 5, and 10 years, and comparing them to the S&P 500. It also provides an in-depth company profile, outlining Sarepta's focus on genetic medicines for rar

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 08:41
Source
Stock Titan
Stocktwits Direct company coverage

SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth

Sarepta Therapeutics (SRPT) stock fell 7% after-hours despite beating Q1 2026 revenue and earnings expectations, primarily due to lower sales of its gene therapy Elevidys. The therapy's sales were impacted by safety concerns and a narrowed addressable patient population. CEO Doug

Tone
Negative 30/100
Event
Earnings
Published
04 Jul 2026 08:40
Source
Stocktwits
TradingView Direct company coverage

Sarepta Therapeutics, Inc. Stock 12‑Month Price Target Cut to $22, Implies 14% Upside

Sarepta Therapeutics, Inc. (SRPT) has seen its average 12-month price target reduced from $22.67 to $22 by 23 analysts, despite forecasts ranging from $5 to $38 per share. This new target implies a 14% potential upside based on the July 2 closing price. The consensus rating for S

Tone
Neutral 50/100
Event
Analyst action
Published
03 Jul 2026 03:11
Source
TradingView
AlphaStreet Direct company coverage

Sarepta Therapeutics Jumps 6.5% Amid Sector-Wide Rally

Sarepta Therapeutics saw its stock surge by 6.5% on Thursday, closing at $19.38 per share amidst a broad sector-wide rally in biotechnology stocks. The gene therapy developer's gain outpaced several peers, fueled by investor rotation into the sector rather than company-specific n

Tone
Positive 70/100
Event
Market update
Published
02 Jul 2026 16:10
Source
AlphaStreet
BioSpace Direct company coverage

Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail

Sarepta Therapeutics has secured an early 2027 FDA decision for full approval of its Duchenne muscular dystrophy exon-skipping therapies, Amondys 45 and Vyondys 53, despite their failure to improve motor function in a confirmatory Phase 3 trial. The FDA's acceptance of the applic

Tone
Positive 64/100
Event
Regulatory and legal
Published
01 Jul 2026 11:39
Source
BioSpace
BioPharm International Direct company coverage

FDA Accepts sNDAs for Sarepta's AMONDYS 45 and VYONDYS 53, Targeting Traditional Approval in Duchenne

The FDA has accepted Sarepta's supplemental New Drug Applications (sNDAs) for Amondys 45 and Vyondys 53, aiming to convert their accelerated approvals to traditional approvals for Duchenne muscular dystrophy. The decision is based on data from the Phase 3 ESSENCE confirmatory tri

Tone
Positive 81/100
Event
Regulatory and legal
Published
01 Jul 2026 06:39
Source
BioPharm International